|

T-Bren, Dose level 1 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: BL-M07D1, T-Bren, Trastuzumab Brengitecan

Pipeline

Phase 3: 1

Top Sponsors

  • SystImmune Inc.1

Indications

  • Urothelial Carcinoma of the Urinary Bladder1
  • Bladder Ca1
  • Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable1
  • Bladder Cancer (BC)1
  • Bladder Cancer Recurrent1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.